Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
$25.79
-0.6%
$25.36
$16.54
$28.13
$385.36M0.7660,336 shs35,868 shs
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$1.15
$1.15
$0.98
$1.89
$35.95M-0.6862,097 shs10,269 shs
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$64.23
+2.3%
$65.21
$44.27
$74.64
$1.41B0.8795,025 shs69,725 shs
SI-BONE, Inc. stock logo
SIBN
SI-BONE
$15.27
-1.9%
$16.97
$14.84
$29.51
$638.97M1.2334,512 shs312,421 shs
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
-0.62%+1.10%+1.30%+11.26%-3.37%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
0.00%-1.71%-2.54%-10.16%-17.86%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
+2.33%+0.17%-3.33%+11.78%+17.02%
SI-BONE, Inc. stock logo
SIBN
SI-BONE
-1.86%-0.46%+0.13%-20.72%-29.08%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
3.1875 of 5 stars
2.31.00.03.61.91.71.9
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.8133 of 5 stars
3.02.00.04.40.60.00.6
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
2.9658 of 5 stars
1.33.04.20.01.23.32.5
SI-BONE, Inc. stock logo
SIBN
SI-BONE
4.2334 of 5 stars
4.52.00.03.31.42.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
2.50
Moderate Buy$29.5014.39% Upside
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.00
Hold$2.50117.39% Upside
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
2.67
Moderate Buy$68.206.18% Upside
SI-BONE, Inc. stock logo
SIBN
SI-BONE
3.00
Buy$26.6774.63% Upside

Current Analyst Ratings

Latest ANIK, CODX, LMAT, and SIBN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/3/2024
SI-BONE, Inc. stock logo
SIBN
SI-BONE
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00
3/28/2024
SI-BONE, Inc. stock logo
SIBN
SI-BONE
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$25.00
3/15/2024
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$3.00 ➝ $2.50
3/14/2024
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$22.00
3/14/2024
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$29.00 ➝ $37.00
2/28/2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$66.00 ➝ $69.00
2/27/2024
SI-BONE, Inc. stock logo
SIBN
SI-BONE
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$25.00 ➝ $26.00
2/27/2024
SI-BONE, Inc. stock logo
SIBN
SI-BONE
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$25.00
2/27/2024
SI-BONE, Inc. stock logo
SIBN
SI-BONE
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$26.00 ➝ $24.00
2/6/2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Weight
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
$166.66M2.30$4.89 per share5.27$14.50 per share1.78
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$6.81M5.28N/AN/A$2.81 per share0.41
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$193.48M7.45$1.83 per share35.15$13.38 per share4.80
SI-BONE, Inc. stock logo
SIBN
SI-BONE
$138.89M4.51N/AN/A$4.18 per share3.65

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
-$82.67M-$5.65N/A19.102.32-49.60%-2.10%-1.71%5/8/2024 (Confirmed)
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-$35.33M-$1.21N/AN/A-518.69%-35.37%-32.58%5/9/2024 (Estimated)
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$30.10M$1.3447.9335.292.7015.56%10.57%9.15%5/2/2024 (Confirmed)
SI-BONE, Inc. stock logo
SIBN
SI-BONE
-$43.34M-$1.14N/AN/AN/A-31.20%-28.22%-20.53%5/6/2024 (Confirmed)

Latest ANIK, CODX, LMAT, and SIBN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
-$0.19N/A+$0.19N/AN/AN/A  
5/6/2024N/A
SI-BONE, Inc. stock logo
SIBN
SI-BONE
-$0.29N/A+$0.29N/AN/AN/A  
5/2/2024N/A
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.39N/A-$0.39N/AN/AN/A  
3/14/2024Q4 2023
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A-$0.50-$0.50-$0.50$3.63 million$3.56 million
3/13/2024Q4 2023
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
-$0.15$0.05+$0.20$4.40$41.51 million$42.97 million
2/27/2024Q4 2023
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.36$0.38+$0.02$0.38$49.01 million$48.90 million    
2/26/2024Q4 2023
SI-BONE, Inc. stock logo
SIBN
SI-BONE
-$0.29-$0.27+$0.02-$0.27$38.60 million$38.86 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
N/AN/AN/AN/AN/A
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/AN/AN/AN/AN/A
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.641.00%+13.80%47.76%13 Years
SI-BONE, Inc. stock logo
SIBN
SI-BONE
N/AN/AN/AN/AN/A

Latest ANIK, CODX, LMAT, and SIBN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/21/2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Quarterly$0.160.9%3/13/20243/14/20243/28/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
N/A
5.26
3.76
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A
10.81
10.52
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
N/A
6.51
4.57
SI-BONE, Inc. stock logo
SIBN
SI-BONE
0.21
9.01
8.15

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
91.53%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
14.99%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
84.64%
SI-BONE, Inc. stock logo
SIBN
SI-BONE
98.11%

Insider Ownership

CompanyInsider Ownership
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
5.85%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.40%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
10.79%
SI-BONE, Inc. stock logo
SIBN
SI-BONE
5.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
35714.85 million13.98 millionOptionable
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
15531.26 million30.51 millionOptionable
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
61422.45 million20.02 millionOptionable
SI-BONE, Inc. stock logo
SIBN
SI-BONE
34441.06 million38.85 millionOptionable

ANIK, CODX, LMAT, and SIBN Headlines

SourceHeadline
SI-BONE (NASDAQ:SIBN) Reaches New 1-Year Low at $14.84SI-BONE (NASDAQ:SIBN) Reaches New 1-Year Low at $14.84
americanbankingnews.com - April 17 at 5:44 AM
Allspring Global Investments Holdings LLC Cuts Holdings in SI-BONE, Inc. (NASDAQ:SIBN)Allspring Global Investments Holdings LLC Cuts Holdings in SI-BONE, Inc. (NASDAQ:SIBN)
marketbeat.com - April 17 at 5:01 AM
SI-BONE To Report First Quarter 2024 Financial Results on May 6, 2024SI-BONE To Report First Quarter 2024 Financial Results on May 6, 2024
globenewswire.com - April 15 at 4:09 PM
SI-BONE (NASDAQ:SIBN) Sets New 52-Week Low at $14.84SI-BONE (NASDAQ:SIBN) Sets New 52-Week Low at $14.84
marketbeat.com - April 15 at 10:57 AM
SI-BONE (NASDAQ:SIBN) Shares Up 4.6%SI-BONE (NASDAQ:SIBN) Shares Up 4.6%
marketbeat.com - April 9 at 1:50 PM
SI-BONE, Inc. (NASDAQ:SIBN) Stock Position Lifted by Vanguard Group Inc.SI-BONE, Inc. (NASDAQ:SIBN) Stock Position Lifted by Vanguard Group Inc.
marketbeat.com - April 9 at 4:08 AM
Kent Lake Capital LLC Has $8.40 Million Stake in SI-BONE, Inc. (NASDAQ:SIBN)Kent Lake Capital LLC Has $8.40 Million Stake in SI-BONE, Inc. (NASDAQ:SIBN)
marketbeat.com - April 6 at 7:28 PM
Insider Selling: SI-BONE, Inc. (NASDAQ:SIBN) CFO Sells 2,425 Shares of StockInsider Selling: SI-BONE, Inc. (NASDAQ:SIBN) CFO Sells 2,425 Shares of Stock
insidertrades.com - April 5 at 7:46 AM
SI-BONE, Inc. (NASDAQ:SIBN) CFO Sells $37,466.25 in StockSI-BONE, Inc. (NASDAQ:SIBN) CFO Sells $37,466.25 in Stock
marketbeat.com - April 4 at 9:43 PM
SI-Bone’s Favorable Outlook and Buy Rating Amidst Stable Medical Coverage and Growth ProspectsSI-Bone’s Favorable Outlook and Buy Rating Amidst Stable Medical Coverage and Growth Prospects
markets.businessinsider.com - April 3 at 10:32 PM
SI-BONE (NASDAQ:SIBN) Receives "Buy" Rating from Needham & Company LLCSI-BONE (NASDAQ:SIBN) Receives "Buy" Rating from Needham & Company LLC
marketbeat.com - April 3 at 12:14 PM
Assenagon Asset Management S.A. Acquires 201,615 Shares of SI-BONE, Inc. (NASDAQ:SIBN)Assenagon Asset Management S.A. Acquires 201,615 Shares of SI-BONE, Inc. (NASDAQ:SIBN)
marketbeat.com - March 30 at 4:51 AM
Peeling Back The Layers: Exploring SI-BONE Through Analyst InsightsPeeling Back The Layers: Exploring SI-BONE Through Analyst Insights
markets.businessinsider.com - March 28 at 7:19 PM
SI-BONE (NASDAQ:SIBN) Research Coverage Started at Piper SandlerSI-BONE (NASDAQ:SIBN) Research Coverage Started at Piper Sandler
marketbeat.com - March 28 at 8:28 AM
Insider Selling: SI-BONE, Inc. (NASDAQ:SIBN) Director Sells 2,500 Shares of StockInsider Selling: SI-BONE, Inc. (NASDAQ:SIBN) Director Sells 2,500 Shares of Stock
insidertrades.com - March 15 at 11:59 AM
SI-BONE, Inc. (NASDAQ:SIBN) Insider Sells $56,010.60 in StockSI-BONE, Inc. (NASDAQ:SIBN) Insider Sells $56,010.60 in Stock
insidertrades.com - March 15 at 11:42 AM
Buy Rating Affirmed for SI-Bone on Expansion and Market Growth StrategiesBuy Rating Affirmed for SI-Bone on Expansion and Market Growth Strategies
markets.businessinsider.com - March 13 at 4:07 PM
SIBN Apr 2024 2.500 putSIBN Apr 2024 2.500 put
finance.yahoo.com - March 10 at 7:08 PM
SIBN Jul 2024 10.000 putSIBN Jul 2024 10.000 put
finance.yahoo.com - March 10 at 7:08 PM
SI-BONE to Present at Barclays 26th Annual Global Healthcare Conference on March 12, 2024SI-BONE to Present at Barclays 26th Annual Global Healthcare Conference on March 12, 2024
globenewswire.com - March 4 at 4:09 PM
When Will SI-BONE, Inc. (NASDAQ:SIBN) Become Profitable?When Will SI-BONE, Inc. (NASDAQ:SIBN) Become Profitable?
finance.yahoo.com - February 28 at 8:48 AM
SI-BONE Shares Drop 14% Following 4Q LossSI-BONE Shares Drop 14% Following 4Q Loss
marketwatch.com - February 27 at 2:57 PM
Beyond The Numbers: 4 Analysts Discuss SI-BONE StockBeyond The Numbers: 4 Analysts Discuss SI-BONE Stock
markets.businessinsider.com - February 27 at 2:57 PM
Si-Bone: Q4 Earnings SnapshotSi-Bone: Q4 Earnings Snapshot
thehour.com - February 26 at 7:19 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Anika Therapeutics logo

Anika Therapeutics

NASDAQ:ANIK
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Co-Diagnostics logo

Co-Diagnostics

NASDAQ:CODX
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
LeMaitre Vascular logo

LeMaitre Vascular

NASDAQ:LMAT
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
SI-BONE logo

SI-BONE

NASDAQ:SIBN
SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.